Papers/PMID:39289667
The effectiveness of phytosomal curcumin on clinical and laboratory parameters of patients with multiple trauma admitted to the intensive care unit: a double-blind randomized placebo-controlled trial.
BMC complementary medicine and therapies2024The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
curcumin — decreases C-reactive protein concentration
Evidence strength: moderate.Findingreplicated ×5“A significant reduction in serum BIL-T and CRP levels and a significant increase in serum K levels were observed in the curcumin group compared to the placebo group.”
Quoted verbatim from The effectiveness of phytosomal curcumin on clinical and laboratory parameters of patients with multiple trauma admitted to the intensive care unit: a double-blind randomized placebo-controlled trial.. - Study
- RCT
- Duration
- 7 days
- Dose
- 500 mg phytosomal curcumin daily (two 250 mg capsules, each 20% curcuminoids and 20% phosphatidylserine) with enteral feeding for 7 days
- Population
- Critically ill adults with multiple trauma in a trauma ICU, receiving enteral tube feeding and standard care in both arms; 7-day intervention
The effectiveness of phytosomal curcumin on clinical and laboratory parameters of patients with multiple trauma admitted to the intensive care unit: a double-blind randomized placebo-controlled trial.2024PMID:3928966710.1186/s12906-024-04639-3Permalink